Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590724 | 1.00 | NR1H2 (0.69) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL2222982 | 0.95 | ESR2 (0.70) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL31084557 | 0.95 | ESR2 (0.70) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL31281068 | 0.92 | ESR2 (0.59) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL12608362 | 0.92 | ESR2 (0.59) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL3872976 | 0.89 | HDAC1 (0.67) | NR1H2ESR2HDAC1MAPK1DDB1 | |
| SCHEMBL30091900 | 0.89 | HDAC1 (0.67) | NR1H2ESR2HDAC1MAPK1DDB1 | |
| SCHEMBL13538178 | 0.84 | ESR2 (0.69) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL3185199 | 0.83 | HDAC1 (0.64) | NR1H2ESR2HDAC1MAPK1MAPT | |
| SCHEMBL3178393 | 0.83 | HDAC1 (0.64) | NR1H2ESR2HDAC1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240174659-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| CN-117956996-A | Compounds and methods for YAP/TEAD modulation and indications therefor | OPNA 生物公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-9962388-B2 | Pyrrolopyrimidine compounds used as TLR7 agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3190113-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
| EP-3190113-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016023511-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | 正大天晴药业集团股份有限公司 | 2016-02-18 | — | — | WO | disclosed |
| EP-1501803-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174659-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | NR1H2 89/4885ESR2 723/4885HDAC1 1830/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | NR1H2 407/4885ESR2 3660/4885HDAC1 2/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | NR1H2 1847/4885ESR2 1378/4885HDAC1 242/4885 |
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | NR1H2 2436/4885ESR2 2340/4885HDAC1 72/4885 |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | TLR7, TLR9, TLR1 | NR1H2 528/4885ESR2 3207/4885HDAC1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.